Laura A. Marlow

Jacksonville College — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

28h-index3.8kcitations149works3.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer, Lipids, and Metabolism(34), Thyroid Cancer Diagnosis and Treatment(21), Renal cell carcinoma treatment(17), Prostate Cancer Treatment and Research(17), Cancer, Hypoxia, and Metabolism(17)

Publications149 total

Supplementary Figure 4 from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
2024Open Access
Supplementary Figure 6 from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
2024Open Access
Supplementary Figure 6 from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
2024Open Access
Supplementary Figure 3 from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
2024Open Access
Data from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
2024Open Access
Supplementary Figure 1 from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
2024Open Access
Supplementary Figure 4 from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
2024Open Access
Supplementary Figure 7 from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
2024Open Access
Supplementary Figure 2 from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
2024Open Access
Supplementary Figure 2 from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
2024Open Access
Supplementary Figure 5 from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
2024Open Access
Supplementary Figure 5 from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
2024Open Access
Supplementary Figure 1 from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
2024Open Access
Data from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
2024Open Access
Supplementary Figure 7 from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
2024Open Access
Supplementary Figure 3 from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
2024Open Access
Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
Molecular Cancer Therapeutics·2024· 4 cited
The genomic and evolutionary landscapes of anaplastic thyroid carcinoma
Cell Reports·2024· 60 citedOpen Access
HPR63 Plasma Last Liter Economics and Its Impact on the Costs of Major Human Polyvalent Immunoglobulins in Europe
Value in Health·2023· 1 citedOpen Access
CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas
Frontiers in Endocrinology·2023· 8 citedOpen Access
page 1 of 8Next →

Frequent Co-authors

John A. Copland(44), Han W. Tun(17), Robert C. Smallridge(16), Christina A. Von Roemeling(14), Simon Cooper(11), Kevin J. Wu(7), Derek C. Radisky(7), Stefan K. Grebe(6), James L. Miller(5), Gerardo Colón‐Otero(5), Kumar Sambamurti(4), Joshua Klopper(3), Jeffrey A. Knauf(3), James A. Fagin(3), Bryan R. Haugen(3), Thomas R. Caulfield(3), Winston Tan(3), Pamela Kreinest(3), Ying C. Henderson(3), Stephen Y. Lai(3)